VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Using biomarkers to identify molecular lesions and monitor response to treatment in multiple myeloma

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, comments on the use of biomarkers to identify molecular lesions including mutations, translocations, and amplifications in patients with multiple myeloma, and to monitor treatment response with the aim to tailor therapies to each patient. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter